• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 12, 2014

View Archived Issues

Other news to note

Biomarin Pharmaceutical Inc., of San Rafael, Calif., selected a new drug development candidate, BMN 250, a fusion of alpha-N-acetyglucosaminidase with a peptide derived from insulin-like growth factor 2 for the treatment of Sanfilippo B syndrome or Mucopolysaccharidosis type IIIB. Read More

Clinic roundup

Cempra Inc., of Chapel Hill, N.C., said solithromycin demonstrated no QT effects at single intravenous doses of 800 mg in a 48-subject study. Read More

Stock Movers

Read More

Financings roundup

Auspex Pharmaceuticals Inc., of La Jolla, Calif., said it completed its initial public offering of 8.05 million shares of common stock at $12 each. Read More

Earnings roundup

Ligand Pharmaceuticals Inc., of San Diego, reported that total revenues for 2013 increased 56 percent to $49 million compared with $31.4 million for 2012. Read More

New Seventure fund to back microbiome-related drugs and diagnostics

LONDON – Venture capital firm Seventure Partners is poised to make two investments from a new €120 million (US$164.1 million) fund established to focus on commercializing emerging research in the workings of the microbiome and its applications in therapeutics, biomarkers and companion diagnostics. Read More

GAO urges FDA to become proactive in dealing with shortages

In focusing on individual drug shortages, the FDA is missing opportunities to proactively prevent and mitigate shortages in general, according to the Government Accountability Office (GAO). Read More

Third Rock’s Voyager blasting off with $45M for CNS gene therapy

Fueled by $45 million in Series A money, gene therapy player Voyager Therapeutics Inc. is expected to make public today the details of its adeno-associated virus (AAV) approach in central nervous system (CNS) disorders. Read More

Puma Biotechnology prices public offering and raises $120M

Los Angeles-based Puma Biotechnology Inc. is on a roll. Fresh off receiving a favorable decision from the European Patent Office last week, which upheld the claims related to its licensed European patent that were being opposed by Boehringer Ingelheim International GmbH, the company leveraged its soaring share price by raising $120 million from an underwritten public offering – selling 979,592 shares of its common stock at $122.50 each. Read More

Big pharma getting less acquisitive but more creative in dealmaking

NEW YORK – With capital markets bustling for biopharma, the fact that the number of M&A deals stayed flat in 2013 compared to 2012 isn’t surprising; what is surprising, perhaps, is that big pharma, which had been expected to wow with multiple mega M&A deals, instead, kept a low profile. Read More

Ofirmev sets brisk tempo for $1.3B Cadence Pharmaceuticals acquisition

The acquisition of Cadence Pharmaceuticals Inc. by Mallinckrodt plc for $14 per share in cash, or approximately $1.3 billion on a fully diluted basis, demonstrated that a single asset can still beat the drums when it comes to deal terms. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe